PL1646720T3 - Przeciwciała przeciw receptorowi insulino-podobnego czynnika wzrostowego I oraz ich zastosowania - Google Patents

Przeciwciała przeciw receptorowi insulino-podobnego czynnika wzrostowego I oraz ich zastosowania

Info

Publication number
PL1646720T3
PL1646720T3 PL04763146T PL04763146T PL1646720T3 PL 1646720 T3 PL1646720 T3 PL 1646720T3 PL 04763146 T PL04763146 T PL 04763146T PL 04763146 T PL04763146 T PL 04763146T PL 1646720 T3 PL1646720 T3 PL 1646720T3
Authority
PL
Poland
Prior art keywords
receptor
growth factor
antibodies against
against insulin
insulin
Prior art date
Application number
PL04763146T
Other languages
English (en)
Inventor
Yvo Graus
Erhard Kopetzki
Klaus-Peter Kuenkele
Olaf Mundigl
Paul Parren
Frank Rebers
Ralf Schumacher
De Winkel Jan Van
Vugt Martine Van
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1646720T3 publication Critical patent/PL1646720T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL04763146T 2003-07-10 2004-07-09 Przeciwciała przeciw receptorowi insulino-podobnego czynnika wzrostowego I oraz ich zastosowania PL1646720T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03015526 2003-07-10
PCT/EP2004/007562 WO2005005635A2 (en) 2003-07-10 2004-07-09 Antibodies against insulin-like growth factor i receptor and uses thereof
EP04763146A EP1646720B1 (en) 2003-07-10 2004-07-09 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (1)

Publication Number Publication Date
PL1646720T3 true PL1646720T3 (pl) 2009-04-30

Family

ID=33560758

Family Applications (3)

Application Number Title Priority Date Filing Date
PL04763146T PL1646720T3 (pl) 2003-07-10 2004-07-09 Przeciwciała przeciw receptorowi insulino-podobnego czynnika wzrostowego I oraz ich zastosowania
PL10180710T PL2272873T3 (pl) 2003-07-10 2004-07-09 Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
PL08007731T PL1959014T3 (pl) 2003-07-10 2004-07-09 Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I oraz ich zastosowania

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL10180710T PL2272873T3 (pl) 2003-07-10 2004-07-09 Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
PL08007731T PL1959014T3 (pl) 2003-07-10 2004-07-09 Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I oraz ich zastosowania

Country Status (29)

Country Link
US (3) US7579157B2 (pl)
EP (4) EP1646720B1 (pl)
JP (2) JP4276262B2 (pl)
KR (1) KR100795745B1 (pl)
CN (1) CN100453645C (pl)
AR (1) AR046071A1 (pl)
AT (2) ATE502959T1 (pl)
AU (3) AU2004256215B2 (pl)
BR (1) BRPI0412478B8 (pl)
CA (1) CA2532173C (pl)
CO (1) CO5640053A1 (pl)
CY (1) CY1116227T1 (pl)
DE (2) DE602004017614D1 (pl)
DK (3) DK1646720T3 (pl)
ES (3) ES2534638T3 (pl)
HK (1) HK1094713A1 (pl)
IL (1) IL172925A (pl)
MX (1) MXPA06000270A (pl)
MY (1) MY140209A (pl)
NO (2) NO339935B1 (pl)
NZ (1) NZ544455A (pl)
PL (3) PL1646720T3 (pl)
PT (3) PT2272873E (pl)
RU (2) RU2363706C2 (pl)
SG (1) SG129437A1 (pl)
SI (1) SI2272873T1 (pl)
TW (1) TWI290147B (pl)
WO (1) WO2005005635A2 (pl)
ZA (1) ZA200600181B (pl)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165256A0 (en) * 2002-05-24 2005-12-18 Schering Corp Neutralizing human anti-igfr antibody
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
EP2322215A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
ATE493442T1 (de) * 2004-12-03 2011-01-15 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
MX2007016306A (es) * 2005-06-15 2008-03-07 Schering Corp Formulaciones de anticuerpo anti-igf1r.
ES2452115T3 (es) 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
DE602006021335D1 (de) 2005-10-21 2011-05-26 Hoffmann La Roche Methode zur rekombinanten expression eines polyeptids
US7892790B2 (en) 2005-10-28 2011-02-22 Hoffmann-La Roche Inc. Protein expression in rodent cells
UA95945C2 (ru) * 2006-02-03 2011-09-26 Имклоун Ллк Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12
KR101402592B1 (ko) * 2006-03-06 2014-06-17 에스케이바이오팜 주식회사 피록시캄-무기물 복합체를 포함하는 경피투여 조성물 및이를 이용한 패치시스템
AU2007222584B2 (en) 2006-03-09 2012-07-12 F. Hoffmann-La Roche Ag Anti-drug antibody assay
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
KR20080104160A (ko) * 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008031532A1 (en) 2006-09-12 2008-03-20 F. Hoffmann-La Roche Ag Anti-drug antibody assay
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) * 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
ES2375242T3 (es) 2007-02-27 2012-02-28 F. Hoffmann-La Roche Ag Método para la evalución de la actividad inhibitoria de anticuerpos contra el receptor del factor de crecimiento i de tipo insulina.
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
AU2008228823A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
WO2008135380A1 (en) 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
ES2665920T3 (es) * 2007-06-29 2018-04-30 F. Hoffmann-La Roche Ag Mutante de cadena pesada para mejorar la producción de inmunoglobulina
US20090130105A1 (en) * 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
CA2698103A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
US8383114B2 (en) * 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
SI2573568T1 (sl) 2007-12-15 2015-05-29 F. Hoffmann-La Roche Ag Razlikovalni test
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
AU2009296297A1 (en) * 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
CN103396487A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
SG174606A1 (en) 2009-03-30 2011-11-28 Hoffmann La Roche A method for avoiding glass fogging
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
BRPI1010297A2 (pt) 2009-04-07 2017-06-06 Roche Glycart Ag anticorpos biespecíficos trivalentes.
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
BR112012005893A2 (pt) 2009-09-16 2016-11-22 Genentech Inc hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos
MX337290B (es) 2009-10-19 2016-02-24 Hoffmann La Roche Anticuerpos anti igg reactivos no cruzados.
WO2011050333A1 (en) 2009-10-23 2011-04-28 Amgen Inc. Vial adapter and system
EP2493922B1 (en) 2009-10-26 2017-02-15 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
AR080793A1 (es) * 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
AU2011247610A1 (en) 2010-04-29 2012-12-13 Therading Sa Methods for detecting antibodies
MX2012014180A (es) 2010-06-07 2013-05-06 Amgen Inc Dispositivo de administracion de farmacos.
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
AU2011277999A1 (en) 2010-07-12 2013-01-10 Covx Technologies Ireland Limited Multifunctional Antibody Conjugates
MX2013001305A (es) * 2010-08-05 2013-03-20 Hoffmann La Roche Proteina de fusion de citoquina anti-viral de anticuerpo anti-mhc.
MX360347B (es) 2010-08-17 2018-10-30 F Hoffmann La Roche Ag Star Anticuerpo anti-inmunoglobulina g1 humana.
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
EP2672999A2 (en) 2011-02-10 2013-12-18 Roche Glycart AG Improved immunotherapy
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
EP2691065B1 (en) 2011-03-31 2017-03-01 Amgen Inc. Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
CA2828662A1 (en) 2011-04-20 2012-10-26 Roche Glycart Ag Method and constructs for the ph dependent passage of the blood-brain-barrier
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
KR101684750B1 (ko) 2011-09-23 2016-12-08 로슈 글리카트 아게 이중특이적 항-egfr/항-igf-1r 항체
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
IL308846A (en) 2011-10-14 2024-01-01 Amgen Inc Syringe and assembly method
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
ES2848732T3 (es) 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
MX2015006343A (es) 2012-11-21 2015-10-05 Amgen Inc Dispositivo de administracion de farmacos.
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CA2904661C (en) 2013-03-15 2022-03-15 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CN113559363B (zh) 2013-03-22 2023-10-31 美国安进公司 注射器及装配方法
EP3327034A1 (en) 2013-04-29 2018-05-30 F. Hoffmann-La Roche AG Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
MX365787B (es) 2013-04-29 2019-06-14 Hoffmann La Roche Anticuerpos modificados de unión a receptor de fc neonatal (fcrn) humano y uso de los mismos.
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
WO2015061386A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Injector and method of assembly
CA2926110C (en) 2013-10-24 2023-05-23 Amgen Inc. Drug delivery system with temperature-sensitive control
BR112016014969A2 (pt) 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
AU2015271676A1 (en) 2014-06-03 2016-11-10 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3721922B1 (en) 2016-03-15 2022-05-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
CA3049780A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3592403A1 (en) 2017-03-06 2020-01-15 Amgen Inc. Drug delivery device with activation prevention feature
MX2019010543A (es) 2017-03-07 2019-10-21 Amgen Inc Insercion de agujas por sobrepresion.
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
AU2018245995B2 (en) 2017-03-28 2024-03-07 Amgen Inc. Plunger rod and syringe assembly system and method
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
JP2020527376A (ja) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
EP3706830A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Drug delivery device with placement and flow sensing
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
AU2018368338A1 (en) 2017-11-16 2020-04-09 Amgen Inc. Autoinjector with stall and end point detection
MA50904A (fr) 2017-11-16 2020-09-23 Amgen Inc Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
US11208489B2 (en) 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US11208490B2 (en) 2018-03-05 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
CA3110529A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
TWI824026B (zh) 2018-10-05 2023-12-01 美商安進公司 具有劑量指示器之藥物遞送裝置
MX2021004219A (es) 2018-10-15 2021-05-27 Amgen Inc Dispositivo de administracion de farmacos con mecanismo de amortiguacion.
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
EP3958934A1 (en) 2019-04-24 2022-03-02 Amgen Inc. Syringe sterilization verification assemblies and methods
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR20220151619A (ko) * 2020-02-04 2022-11-15 호라이즌 테라퓨틱스 아일랜드 디에이씨 피부경화증 및 관련된 병태의 치료 방법
CN117320964A (zh) 2021-05-21 2023-12-29 美国安进公司 优化药物容器的灌装方案的方法
WO2023122714A2 (en) * 2021-12-23 2023-06-29 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2023133561A1 (en) 2022-01-09 2023-07-13 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
CA2175892C (en) 1993-11-23 2000-03-07 Paul J. Godowski Kinase receptor activation assay
US6417330B1 (en) * 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
EE05724B1 (et) 2001-01-05 2014-10-15 Pfizer Inc. Antikehad insuliinitaolise kasvufaktori I retseptorile
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
MXPA04006980A (es) 2002-01-18 2004-11-10 Pf Medicament Anticuerpos novedosos anti-receptor del factor de crecimiento i tipo insulina, y usos de los mismos.
IL165256A0 (en) 2002-05-24 2005-12-18 Schering Corp Neutralizing human anti-igfr antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
NZ540971A (en) 2003-02-13 2008-04-30 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
WO2004083248A1 (en) * 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos

Also Published As

Publication number Publication date
EP1959014A2 (en) 2008-08-20
EP2272873B1 (en) 2015-01-28
ES2534638T3 (es) 2015-04-27
JP2009077709A (ja) 2009-04-16
KR100795745B1 (ko) 2008-01-17
DE602004031988D1 (de) 2011-05-05
EP1959014A3 (en) 2009-01-14
ES2360454T3 (es) 2011-06-06
CY1116227T1 (el) 2017-02-08
EP1646720A2 (en) 2006-04-19
CA2532173C (en) 2013-11-12
AR046071A1 (es) 2005-11-23
EP2243835A2 (en) 2010-10-27
PT1646720E (pt) 2008-12-26
PL2272873T3 (pl) 2015-06-30
EP1959014B9 (en) 2011-12-28
CA2532173A1 (en) 2005-01-20
CO5640053A1 (es) 2006-05-31
BRPI0412478B8 (pt) 2021-05-25
US7579157B2 (en) 2009-08-25
DE602004017614D1 (de) 2008-12-18
IL172925A0 (en) 2006-06-11
RU2008126743A (ru) 2010-01-10
CN100453645C (zh) 2009-01-21
HK1094713A1 (en) 2007-04-04
NZ544455A (en) 2008-12-24
DK1959014T3 (da) 2011-04-18
ES2317020T3 (es) 2009-04-16
EP1959014B1 (en) 2011-03-23
ZA200600181B (en) 2007-04-25
US20050008642A1 (en) 2005-01-13
US20080132686A1 (en) 2008-06-05
KR20060054296A (ko) 2006-05-22
TW200513469A (en) 2005-04-16
EP1646720B1 (en) 2008-11-05
JP4276262B2 (ja) 2009-06-10
US20090275126A1 (en) 2009-11-05
PT1959014E (pt) 2011-06-15
RU2363706C2 (ru) 2009-08-10
SI2272873T1 (sl) 2015-05-29
BRPI0412478A (pt) 2006-09-19
ATE413454T1 (de) 2008-11-15
MY140209A (en) 2009-11-30
CN1823163A (zh) 2006-08-23
AU2008202949A1 (en) 2008-07-31
MXPA06000270A (es) 2006-04-07
AU2008207635A1 (en) 2008-09-25
WO2005005635A2 (en) 2005-01-20
NO340438B1 (no) 2017-04-24
IL172925A (en) 2013-07-31
AU2004256215B2 (en) 2008-07-17
EP2272873A2 (en) 2011-01-12
TWI290147B (en) 2007-11-21
DK1959014T5 (da) 2011-06-06
DK1646720T3 (da) 2009-01-05
ATE502959T1 (de) 2011-04-15
PL1959014T3 (pl) 2011-08-31
BRPI0412478B1 (pt) 2020-04-14
EP2272873A3 (en) 2011-09-28
WO2005005635A3 (en) 2005-08-25
RU2006103854A (ru) 2007-08-20
PT2272873E (pt) 2015-04-07
NO20056246L (no) 2006-02-09
US7572897B2 (en) 2009-08-11
JP4464450B2 (ja) 2010-05-19
DK2272873T3 (en) 2015-03-09
AU2008207635B2 (en) 2008-11-20
JP2008538273A (ja) 2008-10-23
AU2008202949B2 (en) 2008-09-25
NO20161389A1 (no) 2016-09-02
NO339935B1 (no) 2017-02-20
SG129437A1 (en) 2007-02-26
ES2360454T9 (es) 2012-02-16
AU2004256215A1 (en) 2005-01-20
EP2243835A3 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
IL172925A0 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
AP2001002365A0 (en) Antibodies to insulin-like growth factor i receptor
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
IL198778A0 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
IL182554A0 (en) Anti-addl antibodies and uses thereof
HK1091116A1 (en) Recombinant il-9 antibodies and uses thereof
PL375405A1 (pl) Przeciwciała
ZA200808597B (en) Antibodies against insulin-like growth factor I receptor and uses thereof
IL178277A0 (en) Irta-5 antibodies and their uses
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
EP1570057A4 (en) AUTOCRINE GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS
IL172510A0 (en) Antibodies and uses thereof
EP1812794A4 (en) AUTOKRINE GROWTH FACTOR RECEPTORS AND METHOD
IL166063A0 (en) Antibodies and uses thereof
GB0226723D0 (en) Antibodies for in vitro use
GB0203552D0 (en) Peptide growth factor
GB0226878D0 (en) Antibodies
EP1809670A4 (en) IRTA-4 ANTIBODIES AND USES THEREOF
GB0227080D0 (en) Antibodies and uses thereof
GB0218235D0 (en) Antibodies
GB0203018D0 (en) Antibodies
HK1072381A1 (en) Cripto-specific antibodies cripto-specific